Sugi Predict

Sugi Predict / Compounds / SCHEMBL499627

SCHEMBL499627

SCHEMBL499627

CC(C)(C)OC(=O)NCCOCCOS(C)(=O)=O

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 8/20 0.46
▸ CA2 P00918 8/20 0.46
▸ CA12 O43570 7/20 0.46
▸ CA9 Q16790 7/20 0.46
▸ TDP1 Q9NUW8 1/20 0.45
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ GAA P10253 1/20 0.43
▸ MAOA P21397 1/20 0.40
▸ MAOB P27338 1/20 0.40
▸ IDO1 P14902 1/20 0.39
▸ BCHE P06276 1/20 0.39
▸ CNR2 P34972 1/20 0.39
▸ EPHX1 P07099 1/20 0.38
▸ ADRB2 P07550 1/20 0.38
▸ HTR1A P08908 1/20 0.38
▸ MALT1 Q9UDY8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21070363 1.00 CA1 (0.46) CA1CA2CA12CA9TDP1
SCHEMBL14740858 1.00 CA1 (0.46) CA1CA2CA12CA9TDP1
SCHEMBL14745097 1.00 CA1 (0.46) CA1CA2CA12CA9TDP1
SCHEMBL31395837 1.00 CA1 (0.46) CA1CA2CA12CA9TDP1
SCHEMBL21070189 1.00 CA1 (0.46) CA1CA2CA12CA9TDP1
SCHEMBL15969366 1.00 CA1 (0.46) CA1CA2CA12CA9TDP1
SCHEMBL14744716 1.00 CA1 (0.46) CA1CA2CA12CA9TDP1
SCHEMBL14745412 1.00 CA1 (0.46) CA1CA2CA12CA9TDP1
SCHEMBL26641014 0.93 TDP1 (0.45) CA1CA2CA12CA9TDP1
SCHEMBL28520852 0.91 TDP1 (0.46) CA1CA2CA12CA9TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747260-A1 MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2026-05-27 — — EP disclosed
EP-4161931-B1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2026-02-18 — — EP disclosed
EP-4653049-A2 CGRP ANTAGONIST COMPOUNDS Nxera Pharma UK Limited (GB) 2025-11-26 — — EP disclosed
EP-4622966-A1 NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF Radionetics Oncology, Inc. (US) 2025-10-01 — — EP disclosed
EP-3983417-B1 CGRP ANTAGONIST COMPOUNDS NXERA PHARMA UK LTD (GB) 2025-09-03 — — EP disclosed
US-20250136616-A1 CGRP ANTAGONIST COMPOUNDS HEPTARES THERAPEUTICS LIMITED (GB) 2025-05-01 — — US disclosed
WO-2025082283-A1 LIGAND COMPOUND OF CYCLOPEPTIDE STRUCTURE, NUCLIDE MARKER THEREOF, PHARMACEUTICAL COMPOSITION, AND USE 四川科伦博泰生物医药股份有限公司 2025-04-24 — — WO disclosed
US-20250059138-A1 CHEMICAL LINKERS SIGMA-ALDRICH CHEMICALS PRIVATE LIMITED (IN) 2025-02-20 — — US disclosed
US-12227521-B2 CGRP antagonist compounds NXERA PHARMA UK LIMITED (GB) 2025-02-18 — — US disclosed
WO-2025021666-A1 MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2025-01-30 — — WO disclosed
US-20030130518-A1 Urea substituted imidazoquinoline ethers COLEY PHARMACEUTICAL GROUP, INC. 2003-07-10 — — US disclosed
US-20030096835-A1 Amido ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2003-05-22 — — US disclosed
US-20020193396-A1 Sulfonamido ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2002-12-19 — — US disclosed
WO-2002046191-A2 UREA SUBSTITUTED IMIDAZOQUINOLINE ETHERS 3M INNOVATIVE PROPERTIES COMPANY (US) 2002-06-13 — — WO disclosed
WO-2002046190-A2 SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2002-06-13 — — WO disclosed
WO-2002046188-A2 AMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2002-06-13 — — WO disclosed
US-6255323-B1 Cyanoguanidine compounds SHIONOGI BIORESEARCH CORP. 2001-07-03 — — US disclosed
WO-2000061561-A1 CYANOGUANIDINE COMPOUNDS SHIONOGI BIORESEARCH CORP. (US) 2000-10-19 — — WO disclosed
US-5773612-A VASOPRESSIN OR OXYTOCIN RECEPTORS SANOFI (FR) 1998-06-30 — — US disclosed
US-5594023-A 1,3-dihydroindol-2-one derivatives substituted in the 3-position by a nitrogen-containing group, their preparation and the pharmaceutical compositions in which they are present SANOFI (FR) 1997-01-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136616-A1 CGRP ANTAGONIST COMPOUNDS CALCRL, CALCR, OPRL1 CA1 4183/4885CA2 2605/4885CA12 4565/4885
US-20250059138-A1 CHEMICAL LINKERS MDM2, ADRM1, USP36 CA1 4785/4885CA2 4824/4885CA12 4620/4885
US-12227521-B2 CGRP antagonist compounds CALCRL, CALCR, OPRL1 CA1 4183/4885CA2 2605/4885CA12 4565/4885
US-20030130518-A1 Urea substituted imidazoquinoline ethers IRF3, EIF2AK2, IFNG CA1 4584/4885CA2 4676/4885CA12 4664/4885
US-20030096835-A1 Amido ether substituted imidazoquinolines IFNG, IRF3, EIF2AK2 CA1 4506/4885CA2 4437/4885CA12 4624/4885
US-20020193396-A1 Sulfonamido ether substituted imidazoquinolines IFNG, IRF3, IL2 CA1 4177/4885CA2 3584/4885CA12 3826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.